title: Amino acid repletion does not decrease muscle protein catabolism during hemodialysis.
abstract: Intradialytic protein catabolism is attributed to loss of amino acids in the dialysate. We investigated the effect of amino acid infusion during hemodialysis (HD) on muscle protein turnover and amino acid transport kinetics by using stable isotopes of phenylalanine, leucine, and lysine in eight patients with end-stage renal disease (ESRD). Subjects were studied at baseline (pre-HD), 2 h of HD without amino acid infusion (HD-O), and 2 h of HD with amino acid infusion (HD+AA). Amino acid depletion during HD-O augmented the outward transport of amino acids from muscle into the vein. Increased delivery of amino acids to the leg during HD+AA facilitated the transport of amino acids from the artery into the intracellular compartment. Increase in muscle protein breakdown was more than the increase in synthesis during HD-O (46.7 vs. 22.3%, P < 0.001). Net balance (nmol.min(-1).100 ml (-1)) was more negative during HD-O compared with pre-HD (-33.7 +/- 1.5 vs. -6.0 +/- 2.3, P < 0.001). Despite an abundant supply of amino acids, the net balance (-16.9 +/- 1.8) did not switch from net release to net uptake. HD+AA induced a proportional increase in muscle protein synthesis and catabolism. Branched chain amino acid catabolism increased significantly from baseline during HD-O and did not decrease during HD+AA. Protein synthesis efficiency, the fraction of amino acid in the intracellular pool that is utilized for muscle protein synthesis decreased from 42.1% pre-HD to 33.7 and 32.6% during HD-O and HD+AA, respectively (P < 0.01). Thus amino acid repletion during HD increased muscle protein synthesis but did not decrease muscle protein breakdown.
authors.affiliation: Division of Nephrology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131-5271, USA. draj@salud.unm.edu
authors.forename: Dominic S C
authors.initials: DS
authors.lastname: Raj
authors.forename: Oladipo
authors.initials: O
authors.lastname: Adeniyi
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Dominic
authors.forename: Michel A
authors.initials: MA
authors.lastname: Boivin
authors.forename: Sandra
authors.initials: S
authors.lastname: McClelland
authors.forename: Antonios H
authors.initials: AH
authors.lastname: Tzamaloukas
authors.forename: Nancy
authors.initials: N
authors.lastname: Morgan
authors.forename: Lawrence
authors.initials: L
authors.lastname: Gonzales
authors.forename: Robert
authors.initials: R
authors.lastname: Wolfe
authors.forename: Arny
authors.initials: A
authors.lastname: Ferrando
mesh_terms: D000328:Adult; D000596:Amino Acids / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000597:Amino Acids, Branched-Chain / Q000378:metabolism; D001692:Biological Transport; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy*; D007700:Kinetics; D008297:Male; D008660:Metabolism; D008875:Middle Aged; D008954:Models, Biological; D009124:Muscle Proteins / Q000378:metabolism*; D006435:Renal Dialysis
chemical_list: D000596:Amino Acids; D000597:Amino Acids, Branched-Chain; D009124:Muscle Proteins